Anal cancer and colon cancer are not the same disease. Despite affecting parts of the digestive tract that sit close together, they develop from different cell types, have different causes, and are treated in fundamentally different ways. The distinction matters because it affects everything from screening to treatment to outlook.
Different Tissues, Different Cancers
The colon is lined with columnar cells, the tall, column-shaped cells that produce mucus and absorb nutrients. Colon cancer almost always starts in these cells, which is why it’s classified as an adenocarcinoma, a cancer of glandular tissue. The anal canal, by contrast, is lined with flat squamous cells, the same type of cell that makes up skin. About 90% of anal cancers are squamous cell carcinomas.
The boundary between these two tissue types is a specific landmark called the squamocolumnar junction, where the lining of the rectum transitions to the lining of the anal canal. That junction is essentially where “colon territory” ends and “anal territory” begins. Even though only a few centimeters separate them, the biology on each side is distinct enough that the cancers arising from them behave like entirely different diseases.
What Causes Each One
The biggest difference in what drives these cancers: HPV. About 91% of anal cancers are caused by the human papillomavirus, the same virus linked to cervical cancer. This makes anal cancer largely an infection-driven disease, and it means the HPV vaccine can significantly reduce risk.
Colon cancer has a completely different risk profile. Its primary drivers are age, family history, inherited gene mutations, inflammatory bowel disease, and lifestyle factors like a diet high in processed meat, obesity, heavy alcohol use, and smoking. HPV plays essentially no role. While some risk factors overlap (smoking increases risk for both), the underlying biology pushing cells toward cancer is different in each case.
Symptoms That Set Them Apart
Both cancers can cause rectal bleeding, changes in bowel habits, fatigue, and unexplained weight loss, which is part of why people confuse them. But each also has symptoms the other typically doesn’t.
- Anal cancer often causes itching or pain around the anus, visible lumps near the anal opening, and pain during bowel movements.
- Colon cancer is more likely to cause abdominal pain, bloating, and a persistent feeling that the bowels haven’t fully emptied.
Anal cancer symptoms tend to be localized, felt right at or near the anus. Colon cancer symptoms are often more diffuse, showing up as general abdominal discomfort or changes in stool consistency that develop gradually over weeks or months.
How They’re Screened For
Colon cancer screening is well established: colonoscopy, typically starting at age 45, is the standard. Anal cancer screening is less standardized and targets specific high-risk groups rather than the general population.
People living with HIV face a 30-fold increased lifetime risk of anal cancer. Organ transplant recipients on immunosuppressive medications have an even more dramatically elevated risk, estimated at 30 to 100 times higher than the general population. For these groups, screening tools include a digital anorectal exam, an anal Pap test (similar in concept to a cervical Pap smear), and HPV testing. If results are abnormal, a procedure called high-resolution anoscopy provides a closer look at the tissue. Leading guidelines recommend annual anal Pap tests for all HIV-positive patients and targeted screening for men who have sex with men and women with a history of abnormal cervical Pap results.
Treatment Looks Very Different
This is one of the starkest contrasts between the two cancers. Colon cancer is primarily treated with surgery. The affected section of the colon is removed, and depending on the stage, chemotherapy follows.
Anal cancer takes the opposite approach. Since 1974, the standard first-line treatment has been concurrent chemotherapy and radiation, a combination known as the Nigro protocol. This approach was a breakthrough because it allowed patients to keep their sphincter intact and avoid a permanent colostomy. Surgery to remove the anus and rectum is now reserved only for cases where chemoradiation fails. For most people with anal cancer, treatment means several weeks of daily radiation combined with chemotherapy, not an operation.
How Staging Differs
Even the way doctors measure how far each cancer has progressed uses different criteria. Anal cancer stages (T1 through T3) are based on tumor size: under 2 cm, 2 to 5 cm, and over 5 cm. Colon and rectal cancer stages are based on how deep the tumor has grown into the intestinal wall and surrounding tissue, regardless of its width.
Lymph node staging also differs in a meaningful way. For anal cancer, staging depends on which lymph nodes are involved. For colon cancer, it depends on how many lymph nodes contain cancer cells. And certain lymph nodes, like those in the groin, count as regional (nearby) disease in anal cancer but would be classified as distant spread in rectal cancer. These differences affect treatment decisions and prognosis.
Survival Rates Compared
When caught early, both cancers have strong survival rates, but the numbers diverge significantly at later stages. For localized anal cancer (confined to the primary site, which accounts for about 40% of cases), the five-year relative survival rate is 85%. Localized colon cancer has a slightly higher rate at 91.5%.
The gap widens dramatically once cancer has spread to distant sites. Distant-stage colon cancer has a five-year survival rate of just 16.2%, while distant-stage anal cancer sits at 36.3%. One reason for this difference is that colon cancer metastasizes to distant organs more frequently, with 23% of cases diagnosed at the distant stage compared to 14% for anal cancer.
How Common Each Cancer Is
Colon cancer is far more common. Colorectal cancer is the third most commonly diagnosed cancer in the United States, while anal cancer is relatively rare, with roughly 8,348 new cases diagnosed per year. The two are not in the same league in terms of prevalence, which is one reason colon cancer has a well-known, population-wide screening program while anal cancer screening remains targeted to high-risk groups.
The incidence of anal cancer has been rising, however, largely driven by HPV infection in immunocompromised populations. This trend reinforces how different its causes are from colon cancer and why prevention strategies, particularly HPV vaccination, could have a significant impact on reducing future cases.